Whole genome sequencing for investigation of age-related chronic disease in HANDLS participants

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

NATIONAL INSTITUTES OF HEALTH OLAO

Contract Value

Not provided

Codes & Classification
Solicitation Number

75N98026R00166

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)

Classification Code

Q301

Additional Details
Set Aside

NONE

Place of Performance

Brooklyn, Maryland, UNITED STATES

SourceSAM
Documents5
The National Institutes of Health (NIH), Office of Logistics and Acquisition Operations (OLAO), has issued a combined synopsis/solicitation for whole genome sequencing (WGS) services to support the Healthy Aging in Neighborhoods of Diversity across the Life Span (HANDLS) study. This procurement seeks to expand ongoing research into the genetic underpinnings of age-related chronic diseases by generating comprehensive genomic data from long-term HANDLS participants. The HANDLS study, which has collected biological samples over a span of 20 years, aims to investigate how genetic variants may contribute to the incidence, prevalence, morbidity, and mortality of chronic diseases associated with aging, particularly within diverse U.S. populations. The ultimate objective is to create a robust, consistent WGS dataset that complements the extensive longitudinal behavioral and health data already amassed by HANDLS, thereby enabling more nuanced analyses of health disparities and disease mechanisms. The contractor will be responsible for processing up to 600 participant samples, some of which have been stored for over a decade. Key requirements and deliverables include: - Preparation and delivery of sample plates suitable for sequencing. - Execution of whole genome sequencing using the NovaSeq X-Plus platform with 25B-300 flow cells, employing 150 bp paired-end runs and the NovaSeq workflow-series 10B sequencing protocol. - Verification of genomic DNA quantity and quality through concentration measurements, volume checks, and agarose gel analysis. - Re-sequencing of samples that meet DNA quality and quantity thresholds but initially fail sequencing-based quality control. - Preparation of PCR-free sequence libraries for all samples. - Sequencing at a minimum depth of 30x coverage with 2×150 base pair runs. - Comprehensive primary and secondary data analysis, including read alignment, variant calling, and a suite of quality control checks (e.g., sex confirmation, detection of duplicates and relatedness, sample identity verification, coverage assessment, contamination checks, and other standard metrics). - Use of the DRAGEN Germline pipeline for alignment and variant calling, followed by joint variant calling to produce a multi-sample VCF file. - Delivery of all sequencing data in a secure, mutually agreed-upon electronic format that ensures participant confidentiality. Data deliverables will include per-sample CRAMs, gVCFs, VCFs, joint-called multi-sample VCF, structural variant and CNV calls, a quality control report, data dictionary, and a sample manifest highlighting any flagged issues. - Provision of written documentation detailing the sequencing pipeline and methodologies employed. - Upon request, participation in NIH laboratory staff meetings and provision of technical consultations. - Return shipment of any remaining samples on dry ice to the Biomedical Research Center in Baltimore, MD. This opportunity is classified under NAICS code 541714 (Research and Development in Biotechnology, except Nanobiotechnology) and Product Service Code Q301. There is no set-aside restriction; the solicitation is open to all qualified entities. The place of performance is Brooklyn, Maryland, United States. The contracting entity is the National Institutes of Health, under the Department of Health and Human Services. The primary point of contact for this procurement is Brian Lind, who can be reached via email at [email protected]. Interested contractors should review the full solicitation and its attachments for detailed specifications and requirements. The notice remains active, with a response deadline of September 24, 2026. All documentation and updates, including responses to questions and a revised statement of work, are available through the official SAM.gov opportunity listing. This procurement represents a significant opportunity for organizations with expertise in high-throughput whole genome sequencing, advanced bioinformatics, and secure data management to contribute to a landmark study in aging and health disparities research.